NICE backtracks on green light for Amgen's Xgeva after change of comparators
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, is rethinking its initial draft yes for Amgen's bone drug Xgeva (denosumab) for preventing skeletal related events in prostate cancer patients with bone metastases. The draft no comes after NICE's appraisal committee decided that best supportive care would be a more suitable comparator in prostate cancer patients rather than bisphosphonates.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.